Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Big Tech Moves Into AI Drug Development

AI summary

TMTPost reported that Anthropic announced the acquisition of one-employee biotechnology company Mithril Medicine, which studies treatments for two rare muscular dystrophies. OpenAI also announced the acquisition of Orchestra Bio and plans to integrate its drug-development workflow coordination technology into Rosalind. Other initiatives include Isomorphic Labs’ drug pipeline, Nvidia and Eli Lilly’s planned AI laboratory, Amazon and Novo Nordisk’s strategic partnership, and Microsoft Discovery. Mithril Medicine’s reported mouse results are preclinical, and its potential entry into human trials by the end of 2028 remains conditional on further research.

(本文作者为 医线Insight,钛媒体经授权发布)

文 | 医线Insight,作者丨张小漫

一家只有一名全职员工的生物技术公司,近期被AI巨头Anthropic宣布收购。

这家公司名叫Mithril Medicine,专注于两种罕见肌营养不良症的治疗研究。创始人Cody Tranbarger借助Claude,在不到18个月的时间里协调了11家外部实验室,将一项潜在疗法从最初的构想推进到实验阶段,并在小鼠实验中取得了积极结果。

如果后续研究进展顺利,相关候选药物最早有望在2028年底进入人体临床试验。

几乎同一时间,OpenAI也宣布收购Orchestra Bio,计划将其药物研发流程协调技术整合进旗下生命科学产品Rosalind。

#Anthropic#OpenAI#Mithril Medicine#Orchestra Bio#Rosalind#Claude#Isomorphic Labs#Nvidia#Eli Lilly#Amazon#Novo Nordisk#Microsoft Discovery

Original · 14 min readRead the original
Group chat

No comments yet. Start the conversation.